Sponsors (10)
The bill standardizes and accelerates FDA regulatory language and implementation—potentially speeding reviews and benefiting patients and researchers—while trading off reduced public notice-and-comment input and some short-term compliance and interpretive burdens.
Scientists, researchers, and hospital sponsors will face clearer, consistent regulatory definitions (e.g., replacing disparate terms with 'nonclinical'), reducing confusion across CFR sections and likely speeding FDA review and approval processes.
Patients with chronic conditions could benefit from more streamlined drug development and faster review timelines because preclinical evidence requirements are stated more clearly.
Federal employees and industry can implement statutory changes more quickly because the interim final rule becomes effective immediately on publication, allowing faster operationalization within the one-year statutory window.
Scientists, researchers, and hospitals lose the usual notice-and-comment period because the rule is immediately effective, limiting public and industry input on important regulatory changes.
Sponsors and research organizations will incur short-term compliance costs to revise submissions, internal procedures, and documentation due to terminology changes (e.g., 'animal' to 'nonclinical').
Technical redesignation of statutory subsections could cause temporary legal or interpretive confusion for federal staff and regulated parties until guidance or the rule clarifies cross-references.
Based on analysis of 2 sections of legislative text.
Introduced February 3, 2025 by Cory Anthony Booker · Last progress December 17, 2025
Requires the HHS Secretary, through the FDA Commissioner, to publish an interim final rule within one year that revises FDA regulations to replace references to "animal" tests/data/studies/models/research with the statutory term "nonclinical" and to add the statutory definition of "nonclinical test" into multiple FDA regulatory provisions. The interim final rule will be effective as soon as it is published (no need to show good cause under the usual notice-and-comment rule). The Act also sets an official short title and makes a technical redesignation of a separate FDA statutory subsection.